Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Tax Provisions (2023 - 2025)

Protalix BioTherapeutics (PLX) has 3 years of Tax Provisions data on record, last reported at -$116000.0 in Q3 2025.

  • For Q3 2025, Tax Provisions fell 119.11% year-over-year to -$116000.0; the TTM value through Sep 2025 reached $1.1 million, up 5550.0%, while the annual FY2024 figure was $1.2 million, 63.48% down from the prior year.
  • Tax Provisions reached -$116000.0 in Q3 2025 per PLX's latest filing, down from $497000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $3.4 million in Q2 2023 and bottomed at -$420000.0 in Q4 2023.
  • Average Tax Provisions over 3 years is $439636.4, with a median of $133000.0 recorded in 2023.
  • Peak YoY movement for Tax Provisions: crashed 170.77% in 2024, then skyrocketed 820.29% in 2025.
  • A 3-year view of Tax Provisions shows it stood at -$420000.0 in 2023, then skyrocketed by 295.71% to $822000.0 in 2024, then tumbled by 114.11% to -$116000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$116000.0 in Q3 2025, $497000.0 in Q2 2025, and -$113000.0 in Q1 2025.